v3.25.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Federal grants $ 5,210,031 $ 2,230,520
Operating expenses:    
Research and development 7,219,437 7,587,473
General and administrative 4,720,728 5,361,234
Total operating expenses 11,940,165 12,948,707
Loss from operations (6,730,134) (10,718,187)
Other income (expense):    
Loss on conversions and change in fair value of convertible notes 146,479
Change in fair value of liability classified warrants 16,292 283,958
Interest expense, net (1,290,444) (353,945)
Other income and expense, net 17,277 15,420
Total other income (expense), net (1,256,875) 91,912
Net loss (7,987,009) (10,626,275)
Net loss attributable to noncontrolling interests (74) (13,201)
Deemed dividend related to warrants down round provision 290 12,937
Net loss attributable to common stockholders $ (7,987,225) $ (10,626,011)
Net loss per basic and diluted share:    
Net loss per share attributable to common stockholders, basic $ (11.45) $ (70.40)
Net loss per share attributable to common stockholders, diluted $ (11.45) $ (70.40)
Weighted average common shares outstanding, basic 697,686 150,937
Weighted average common shares outstanding, diluted 697,686 150,937

Source